Surpass Elite Flow Diverter
Stryker Neurovascular · Decision date Aug 28, 2026
What did the FDA approve?
FDA records P170024/S027 as a supplement to PMA P170024, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Aug 28, 2026.
FDA approval order statement
Approval for a minor labeling update to a clinical warning and Table 13 of the Instructions for Use.
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Neurology
- Decision date
- Aug 28, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P170024/S027
- Regulatory pathway
- PMA supplement
- Applicant
- Stryker Neurovascular
- Product code
- OUT
- Decision code
- APPR
- Decision date
- Aug 28, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Intracranial aneurysm flow diverter.
- Applicant
- Stryker Neurovascular
- Product code
- OUT
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P170024/S024 · Related supplement
Surpass Streamline Flow Diverter
P170024/S026 · Related supplement
Surpass Evolve; Surpass Elite FDS
P170024/S027 received
Application receipt date recorded by FDA.
P170024/S027 · FDA decision
Real-Time Process
Timeline entries are records held by MedtechLedger for P170024. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P170024
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Surpass Streamline Flow DiverterP170024/S024 | Stryker Neurovascular | PMA supplement | Aug 20, 2025 | FDA |
Surpass Evolve; Surpass Elite FDSP170024/S026 | Stryker Neurovascular | PMA supplement | Jun 26, 2026 | FDA |
Explore the linked device profile
Other records with product code OUT
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Micro Therapeutics, Inc. d/b/a ev3 Neurovascular | PMA supplement | Jul 21, 2026 | FDA | |
| Micro Therapeutics, Inc. d/b/a ev3 Neurovascular | PMA supplement | Jun 26, 2026 | FDA | |
| Micro Therapeutics, Inc. d/b/a ev3 Neurovascular | PMA supplement | May 15, 2026 | FDA | |
PIPELINE EMBOLIZATION DEVICEP100018/S052 | Micro Therapeutics, Inc. d/b/a ev3 Neurovascular | PMA supplement | Feb 20, 2026 | FDA |
| Microvention, Inc. | PMA supplement | Nov 2, 2025 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Stryker Neurovascular
- Headquarters
- Not reported
- Brand website
- stryker.com
- FDA applicant address
- 47900 Bayside Pkwy., Fremont, CA, 94538
Sources and methodology
- Original FDA record: P170024/S027
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




